CannaMetrix

Chemical Testing Alone Cannot Anticipate the Potency of Full Spectrum Products Other than Cannabinoid and terpene chemical compositional analysis and inferences of potency therefrom, there has been little to no effort in the industry to validate products for their actual biological potency using biomarkers within the endocannabinoid system. For the non-psychotropic cannabinoids and terpenes, percent composition cannot predict how the human endocannabinoid system will respond to individual purified Cannabinoids and certainly cannot predict how multiple agonist and antagonist compounds within broad or full spectrum products might affect patients. The industry needs to adopt the standards comparable to how drug potency is measured and expressed throughout the pharmaceutical industry, namely, units of activity per drug concentration (i.e. biological potency) as well as chemical composition. CannaMetrix addresses this unmet need through proprietary human cell-based potency testing that will establish a new high bar for the industry in Cannabis products development and product validation.